JP2012503669A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012503669A5 JP2012503669A5 JP2011529223A JP2011529223A JP2012503669A5 JP 2012503669 A5 JP2012503669 A5 JP 2012503669A5 JP 2011529223 A JP2011529223 A JP 2011529223A JP 2011529223 A JP2011529223 A JP 2011529223A JP 2012503669 A5 JP2012503669 A5 JP 2012503669A5
- Authority
- JP
- Japan
- Prior art keywords
- week
- administered
- stage
- patients
- peginterferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 12
- 229960000329 ribavirin Drugs 0.000 claims 12
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 12
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9984908P | 2008-09-24 | 2008-09-24 | |
| US61/099,849 | 2008-09-24 | ||
| US10965508P | 2008-10-30 | 2008-10-30 | |
| US61/109,655 | 2008-10-30 | ||
| US24304109P | 2009-09-16 | 2009-09-16 | |
| US61/243,041 | 2009-09-16 | ||
| PCT/US2009/058218 WO2010036799A1 (en) | 2008-09-24 | 2009-09-24 | Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis " |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012503669A JP2012503669A (ja) | 2012-02-09 |
| JP2012503669A5 true JP2012503669A5 (cg-RX-API-DMAC7.html) | 2012-11-08 |
Family
ID=41396114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529223A Pending JP2012503669A (ja) | 2008-09-24 | 2009-09-24 | 肝炎を治療するためのｐｅｇ−インターフェロン、リバビリンおよびｖｘ−９５０を含む治療レジメ |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20110236351A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2328656A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012503669A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20110074870A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102316935A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009296653A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2738477A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201170484A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL211810A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011003121A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010036799A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| CA2740728A1 (en) * | 2008-10-15 | 2010-04-22 | Intermune, Inc. | Therapeutic antiviral peptides |
| EP2396028A2 (en) * | 2009-02-12 | 2011-12-21 | Vertex Pharmceuticals Incorporated | Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir |
| WO2011041551A1 (en) * | 2009-10-01 | 2011-04-07 | Intermune, Inc. | Therapeutic antiviral peptides |
| AR088408A1 (es) | 2011-10-21 | 2014-05-28 | Abbvie Inc | Metodos para el tratamiento de hcv |
| AU2013201406B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR049297A1 (es) * | 2004-06-08 | 2006-07-12 | Vertex Pharma | Una composicion farmaceutica y dispersiones solidas de vx-950 (inhibidor de la proteasa de hcv ns3/4a) y proceso de obtencion |
| TW201424733A (zh) * | 2004-10-29 | 2014-07-01 | Vertex Pharma | 劑量型式 |
| CA2650616A1 (en) * | 2006-04-26 | 2007-11-08 | Vertex Pharmaceuticals Incorporated | Hepatitis c virus infection biomarkers |
| EP2157974A1 (en) * | 2007-05-21 | 2010-03-03 | Vertex Pharmceuticals Incorporated | Dose forms comprising vx- 950 and their dosage regimen |
-
2009
- 2009-09-24 AU AU2009296653A patent/AU2009296653A1/en not_active Abandoned
- 2009-09-24 KR KR1020117008799A patent/KR20110074870A/ko not_active Withdrawn
- 2009-09-24 EP EP09792953A patent/EP2328656A1/en not_active Withdrawn
- 2009-09-24 WO PCT/US2009/058218 patent/WO2010036799A1/en not_active Ceased
- 2009-09-24 MX MX2011003121A patent/MX2011003121A/es not_active Application Discontinuation
- 2009-09-24 JP JP2011529223A patent/JP2012503669A/ja active Pending
- 2009-09-24 CN CN2009801480304A patent/CN102316935A/zh active Pending
- 2009-09-24 EA EA201170484A patent/EA201170484A1/ru unknown
- 2009-09-24 CA CA2738477A patent/CA2738477A1/en not_active Abandoned
-
2011
- 2011-03-17 IL IL211810A patent/IL211810A0/en unknown
- 2011-03-24 US US13/070,991 patent/US20110236351A1/en not_active Abandoned
-
2012
- 2012-12-18 US US13/718,608 patent/US8871812B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012503669A5 (cg-RX-API-DMAC7.html) | ||
| IN2012MN02896A (cg-RX-API-DMAC7.html) | ||
| TN2009000457A1 (en) | Novel macrocyclic inhibitors of hepatitis c virus replication | |
| JP2011528713A5 (cg-RX-API-DMAC7.html) | ||
| MX2013003634A (es) | Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales. | |
| MD20140058A2 (en) | Compositions and methods for treating hepatitis C virus | |
| JP2012517478A5 (cg-RX-API-DMAC7.html) | ||
| JP2014530874A5 (cg-RX-API-DMAC7.html) | ||
| MY160130A (en) | Hepatitis c virus inhibitors | |
| MX2012003171A (es) | Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c. | |
| IN2012DN02693A (cg-RX-API-DMAC7.html) | ||
| WO2012087976A3 (en) | Novel inhibitors of hepatitis c virus replication | |
| IL217243A (en) | Theophane 2-carboxylic acid derivatives, including pharmaceutical preparations and their uses for the preparation of flaviviridiae virus infections and hepatitis c virus infections | |
| PH12012501216A1 (en) | Hcv combination therapy | |
| MX2010005107A (es) | Componente de silibinina para tratamiento contra hepatitis. | |
| MX2010008148A (es) | Métodos de tratamiento de infecciones virales. | |
| WO2008100867A3 (en) | Novel inhibitors hepatitis c virus replication | |
| WO2011000566A3 (en) | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections | |
| WO2005095403A3 (en) | Macrocyclic compounds as inhibitors of viral replication | |
| IL213861A0 (en) | Cyclosporine derivative for use in the treatment of hcv and hiv infection | |
| WO2009134616A3 (en) | Novel inhibitors of hepatitis c virus replication | |
| PL2186830T3 (pl) | Interferon alfa 2b zmodyfikowany glikolem polietylenowym, jego wytwarzanie i zastosowanie | |
| JP2010520200A5 (cg-RX-API-DMAC7.html) | ||
| JP2014526559A5 (cg-RX-API-DMAC7.html) | ||
| UA91677C2 (ru) | Макроциклические соединения как ингибиторы вирусной репликации |